Month: October 2024

Release – Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease

Posted on by aweinsoff@channelchek.com

Research News and Market Data On OCGN

October 22, 2024

PDF Version

  • Determined the high dose of OCU410ST to be the maximum tolerated dose
  • No serious adverse events have been reported
  • Approved proceeding to Phase 2 using high and medium doses of OCU410ST

MALVERN, Pa., Oct. 22, 2024 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and approved enrollment for the second phase of the Phase 1/2 clinical trial. OCU410ST (AAV5-hRORA) is a novel modifier gene therapy candidate being developed for Stargardt disease.

“The DSMB has recommended moving forward with Phase 2 enrollment, as safety data indicates that OCU410ST appears to be safe and well-tolerated to date,” said Charles Wykoff, MD, PhD, Director of Research, Retina Consultants of Texas & Retina Consultants of America, and a lead study investigator. “The safety and tolerability profile of OCU410ST remains encouraging as the clinical trial has progressed and continues to bring hope to patients with Stargardt disease, which still has no FDA-approved treatments.”

The first phase of the Phase 1/2 clinical trial was an open-label, dose-ranging study that enrolled nine patients to receive either a low (3.75 x 1010 vg/mL), medium (7.5 x 1010 vg/mL), or high (2.25 x 1011 vg/mL) dose of OCU410ST administered via subretinal injection. No serious adverse events (SAEs) have been reported, and the DSMB determined the high dose to be the maximum tolerated dose (MTD).

Stargardt disease is the most common form of inherited macular dystrophy. Symptoms of bilateral central vision loss typically begin in childhood and gradually worsen over time.

“We are enthusiastic about the potential of OCU410ST to be the first one-time novel modifier gene therapy for Stargardt disease,” said Huma Qamar, MD, MPH, Chief Medical Officer of Ocugen. “We are encouraged by the prospect of addressing a substantial unmet medical need for the estimated 100,000 Stargardt patients in the U.S. and Europe.”

The GARDian clinical trial is currently being performed at 6 leading retinal surgery centers across the U.S.

About Stargardt Disease
Stargardt disease is a genetic eye disorder that causes retinal degeneration and vision loss. Stargardt disease is the most common form of inherited macular degeneration. The progressive vision loss associated with Stargardt disease is caused by the degeneration of photoreceptor cells in the central portion of the retina called the macula.

Decreased central vision due to loss of photoreceptors in the macula is the hallmark of Stargardt disease. Some peripheral vision is usually preserved. Stargardt disease typically develops during childhood or adolescence, but the age of onset and rate of progression can vary. The retinal pigment epithelium (RPE), a layer of cells supporting photoreceptors, is also affected in people with Stargardt disease.

About OCU410ST
OCU410ST utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. It represents Ocugen’s modifier gene therapy approach, which is based on Nuclear Hormone Receptor (NHR) RORA that regulates pathway links to Stargardt disease such as lipofuscin formation, oxidative stress, complement formation, inflammation, and cell survival networks.

About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patient’s lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.

Cautionary Note on Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, strategy, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, the ability to initiate new clinical programs; statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations, including, but not limited to, the risks that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing of may not be predictive of the results or success of later clinical trials; and that that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in our annual and periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com

Release – PDS Biotech Announces Presentation of Rationale and Design of First Recurrent Prostate Cancer Trial to Combine an Androgen Receptor Pathway Inhibitor with an Immunocytokine

Posted on by aweinsoff@channelchek.com

Research News and Market Data on PDSB

Study to evaluate PDS01ADC + Xtandi® (Enzalutamide) versus Xtandi® alone to be presented by Dr. Ravi Madan, National Cancer Institute at Cytokines 2024

PRINCETON, N.J., Oct. 22, 2024 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the rationale and trial design for a study evaluating PDS01ADC for the treatment of recurrent prostate cancer will be discussed during an oral presentation at the 12th Annual Meeting of the International Cytokine & Interferon Society (Cytokines 2024) in Seoul, South Korea. Details of the presentation are as follows:

Date: Wednesday, October 23, 2024
Session time: 08:30-10:10 Korean Standard Time (KST)
Session title: Symposium 20 – Cytokine-mediated Translational Approaches of Human Diseases
Presentation time: 09:20-09:32 KST
Presentation title: A Clinical Trial Combining a Tumor Targeting Immunocytokine (PDS01ADC) and Enzalutamide without Testosterone Lowering Therapy in Biochemically Recurrent Prostate Cancer
Presenter: Ravi A. Madan, M.D., Head, Prostate Cancer Clinical Research Section, Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, part of the U.S. National Institutes of Health

About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines. The Company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.

For more information, please visit www.pdsbiotech.com.

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for PDS01ADC, Versamune® HPV (formerly PDS0101), PDS0203 and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning PDS01ADC, Versamune® HPV, PDS0203 and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  

Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation.

Xtandi® is a registered trademark of Astellas Pharma, Inc.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Janine McCargo
6 Degrees
Phone +1 (646) 528-4034
Email: jmccargo@6degreespr.com

Direct Digital Holdings (DRCT) – A Pretty Big Reset

Posted on by cpereira@noblefcm.com


Tuesday, October 22, 2024

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Getting back on track. The company made a substantial step forward by becoming current on its filings. On Tuesday, October 15th, it reported full year 2023, first quarter 2024, and second quarter 2024 results. The delay in its filings was due to the resignation of the company’s previous auditor, Marcum.

Issues unrelated to the audit. During the first half of the year, the company’s Sell-side revenue was disrupted when its largest client paused service, which coincided with a lawsuit with an activist shareholder. The client subsequently reconnected to the company’s SSP, but volumes have not yet fully recovered. This severely disrupted Q2 results and appears will have a lingering effect for the balance of the year.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Fed’s Logan Advocates Gradual Rate Cuts Amid Continued Balance Sheet Reductions

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Fed’s Logan anticipates gradual rate cuts if the economy aligns with expectations.
– The Fed will continue shrinking its balance sheet, with no plans to halt quantitative tightening.
– Logan sees ongoing market liquidity, supporting continued balance sheet reductions.

Federal Reserve Bank of Dallas President Lorie Logan stated on Monday that gradual interest rate cuts are likely on the horizon if the economy evolves as expected. She also emphasized that the Fed can continue to reduce its balance sheet while maintaining market liquidity. Logan’s remarks were delivered at the Securities Industry and Financial Markets Association annual meeting in New York, where she discussed the central bank’s plans for monetary policy normalization.

“If the economy evolves as I currently expect, a strategy of gradually lowering the policy rate toward a more normal or neutral level can help manage the risks and achieve our goals,” said Logan. She acknowledged that the U.S. economy remains strong and stable, though uncertainties persist, especially concerning the labor market and the Fed’s inflation targets.

Market participants are currently divided over whether the Federal Reserve will follow through on its plan for half a percentage point in rate cuts before year-end, as forecasted during the September policy meeting. While inflation has shown signs of easing, recent jobs data indicates a robust labor market, which may lead the Fed to reconsider the pace and size of its rate cuts.

A significant portion of Logan’s remarks centered on the Fed’s ongoing quantitative tightening (QT) efforts, a process that began in 2022 to reduce the central bank’s holdings of mortgage-backed securities and Treasury bonds. These assets were initially purchased to stimulate the economy and stabilize markets during the early stages of the COVID-19 pandemic. The Fed has reduced its balance sheet from a peak of $9 trillion to its current level of $7.1 trillion, with plans to continue shedding assets.

Logan indicated that the Fed sees no immediate need to stop the balance sheet reductions, stating that both QT and rate cuts are essential components of the Fed’s efforts to normalize monetary policy. She emphasized that ample liquidity exists in the financial system, which supports the continuation of the balance sheet drawdown.

“At present, liquidity appears to be more than ample,” Logan noted, adding that one indicator of abundant liquidity is that money market rates continue to remain well below the Fed’s interest on reserve balances rate.

Recent fluctuations in money markets, Logan suggested, are normal and not a cause for concern. “I think it’s important to tolerate normal, modest, temporary pressures of this type so we can get to an efficient balance sheet size,” she said, reinforcing her confidence in the Fed’s current approach.

Looking ahead, Logan expects that the Fed’s reverse repo facility, which allows financial institutions to park excess cash with the central bank, will see minimal usage in the long run. She hinted that reducing the interest rate on the reverse repo facility could encourage participants to move funds back into private markets, further supporting liquidity outside of the central bank.

Logan also dismissed concerns about the Fed needing to sell mortgage-backed securities in the near term, stating that it is “not a near-term issue in my view.” She reiterated that banks should have comprehensive plans to manage liquidity shortfalls and should feel comfortable using the Fed’s Discount Window liquidity facility if needed.

Logan’s comments reflect a measured approach to managing monetary policy as the U.S. economy continues to recover and adjust to post-pandemic conditions. While inflation is cooling, the Fed remains focused on maintaining flexibility and ensuring stability in the financial system.

Release – Travelzoo Q3 2024 Earnings Conference Call on October 23 at 11:00 AM ET

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TZOO

NEW YORK, Oct. 21, 2024 /PRNewswire/ — Travelzoo® (NASDAQ: TZOO):

WHAT:Travelzoo, the club for travel enthusiasts, will host a conference call to discuss the Company’s financial results for the third quarter ended September 30, 2024. Travelzoo will issue a press release reporting its results before the market opens on October 23, 2024.
WHEN:October 23, 2024 at 11:00 AM ET
HOW: A live webcast of Travelzoo’s Q3 2024 earnings conference call can be accessed at http://ir.travelzoo.com/events-presentations. The webcast will be archived within 2 hours of the end of the call and will be available through the same link.
CONTACT:Travelzoo Investor Relations
ir@travelzoo.com

About Travelzoo
We, Travelzoo®, are the club for travel enthusiasts. Our 30 million members receive exclusive offers and one-of-a-kind experiences personally reviewed by our deal experts around the globe. We have our finger on the pulse of outstanding travel, entertainment, and lifestyle experiences. We work in partnership with more than 5,000 top travel suppliers—our long-standing relationships give us access to irresistible deals.

SOURCE Travelzoo

Release – Direct Digital Holdings Announces Strategic $20 Million Equity Reserve Facility to Accelerate Growth Plan

Posted on by aweinsoff@channelchek.com

Research News and Market Data on DRCT

October 21, 2024 9:00 am EDT Download as PDF

HOUSTON, Oct. 21, 2024 /PRNewswire/ — Direct Digital Holdings, Inc. (Nasdaq: DRCT) (“Direct Digital Holdings” or the “Company”), a leading advertising and marketing technology platform operating through its companies Colossus Media, LLC (“Colossus SSP”), Orange142, LLC (“Orange 142”) and Huddled Masses LLC (“Huddled Masses”), today announced the Company has entered into a $20 million Equity Reserve Facility (“ERF”) with New Circle Principal Investments LLC, an affiliate of New Circle Capital LLC (“New Circle”).

Mark D. Walker, CEO and Co-Founder of Direct Digital Holdings, commented, “We are very pleased to announce this $20 million Equity Reserve Facility with New Circle. The funding will enable the expansion of our technology and strategic capabilities, benefiting both publishers and advertisers. It also opens the door to new growth opportunities and strengthens our commitment to increasing shareholder value.”

Under the agreement, at our sole election, New Circle will purchase, from time to time, shares of our Class A common stock up to an aggregate of $20 million over a period of 36 months, subject to the conditions in the agreement. The proceeds of these sales may be used for general corporate purposes. The Company anticipates using such proceeds to reduce debt obligations, strengthen the overall balance sheet, and drive key growth initiatives.  Those key initiatives extend across Direct Digital Holdings’ subsidiaries, and include specifically:

Advancing Innovation for Colossus SSP
The Company expects to make investments to drive technological advancements for Direct Digital Holdings’ supply-side platform (SSP), Colossus SSP, including the development of new segment-based products in carbon and attention. It will also support direct integrations with leading demand-side platforms (DSPs), optimizing supply path efficiency for advertisers. Additionally, the funding will expand Colossus SSP’s efforts to bring underrepresented publishers into the programmatic ecosystem, with their inventory available through the Company.

Enhancing Growth on the Demand Side
On the demand-side, the Company expects that funding will support the unification of Direct Digital Holdings’ advertising consultancy groups, Orange142 and Huddled Masses. This will enable the delivery of new capabilities, particularly in helping clients navigate emerging technologies, such as artificial intelligence (AI) and machine learning (ML), as well as emerging channels such as connected TV (CTV), social media and retail media.

Keith Smith, President and Co-Founder of Direct Digital Holdings, added, “We are pleased to partner with New Circle on this flexible facility which we expect will enhance our financial liquidity, strengthen our shareholder equity and support a host of growth initiatives across both our supply-side and demand-side platforms.”

BJ Arnold, Managing Partner of New Circle, commented, “New Circle is pleased to partner with Direct Digital Holdings, helping to fuel the company’s growth and support their innovative technology and industry-leading approaches to advertising.”

The Company’s right to commence sales of Class A common stock to New Circle are subject to certain conditions, including that a registration statement covering the resale of such shares is declared effective by the SEC. Actual sales of shares of Class A common stock to New Circle under the agreement will depend on a variety of factors to be determined by the Company from time to time, including, among others, market conditions, the trading price of the Common Stock and determinations by the Company as to the appropriate sources of funding and the Company’s operations.

Further information on the financing can be found in the Current Report on Form 8-K filed today with the Securities and Exchange Commission.

Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws that are subject to certain risks, trends and uncertainties. We use words such as “could,” “would,” “may,” “might,” “will,” “expect,” “likely,” “believe,” “continue,” “anticipate,” “estimate,” “intend,” “plan,” “project” and other similar expressions to identify forward-looking statements, but not all forward-looking statements include these words. All of our forward-looking statements involve estimates and uncertainties that could cause actual results to differ materially from those expressed in or implied by the forward-looking statements. Accordingly, any such statements are qualified in their entirety by reference to the information described under the caption “Risk Factors” and elsewhere in our most recent Annual Report on Form 10 K (the “Form 10-K”) and subsequent periodic and or current reports filed with the Securities and Exchange Commission (the “SEC”).

The forward-looking statements contained in this press release are based on assumptions that we have made in light of our industry experience and our perceptions of historical trends, current conditions, expected future developments and other factors we believe are appropriate under the circumstances. As you read and consider this press release, you should understand that these statements are not guarantees of performance or results. They involve risks, uncertainties (many of which are beyond our control) and assumptions.

Although we believe that these forward-looking statements are based on reasonable assumptions, you should be aware that many factors could affect our actual operating and financial performance and cause our performance to differ materially from the performance expressed in or implied by the forward-looking statements. We believe these factors include, but are not limited to, the following: the conditions to our ability to sell Class A common stock to New Circle, including the effectiveness of the registration statement registering the resale by New Circle of the shares of Class A common stock; the restrictions and covenants imposed upon us by our credit facilities; the substantial doubt about our ability to continue as a going concern, which may hinder our ability to obtain future financing; our ability to secure additional financing to meet our capital needs; our ineligibility to file short-form registration statements on Form S-3, which may impair our ability to raise capital; our failure to satisfy applicable listing standards of the Nasdaq Capital Market resulting in a potential delisting of our common stock; failure to remedy any listing deficiencies noted in the deficiency letters from the Listing Qualifications Department of The Nasdaq Stock Market LLC; the risk that the Listing Qualifications Department of The Nasdaq Stock Market LLC does not accept the Company’s plan to regain compliance with applicable rules to maintain its listing on The Nasdaq Capital Market;  costs, risks and uncertainties related to the restatement of certain prior period financial statements;  any significant fluctuations caused by our high customer concentration; risks related to non-payment by our clients; reputational and other harms caused by our failure to detect advertising fraud; operational and performance issues with our platform, whether real or perceived, including a failure to respond to technological changes or to upgrade our technology systems; restrictions on the use of third-party “cookies,” mobile device IDs or other tracking technologies, which could diminish our platform’s effectiveness; unfavorable publicity and negative public perception about our industry, particularly concerns regarding data privacy and security relating to our industry’s technology and practices, and any perceived failure to comply with laws and industry self-regulation; our failure to manage our growth effectively; the difficulty in identifying and integrating any future acquisitions or strategic investments; any changes or developments in legislative, judicial, regulatory or cultural environments related to information collection, use and processing; challenges related to our buy-side clients that are destination marketing organizations and that operate as public/private partnerships; any strain on our resources or diversion of our management’s attention as a result of being a public company; the intense competition of the digital advertising industry and our ability to effectively compete against current and future competitors; any significant inadvertent disclosure or breach of confidential and/or personal information we hold, or of the security of our or our customers’, suppliers’ or other partners’ computer systems; as a holding company, we depend on distributions from Direct Digital Holdings, LLC (“DDH LLC”) to pay our taxes, expenses (including payments under the Tax Receivable Agreement) and any amount of any dividends we may pay to the holders of our common stock; the fact that DDH LLC is controlled by DDM, whose interest may differ from those of our public stockholders; any failure by us to maintain or implement effective internal controls or to detect fraud; and other factors and assumptions discussed in our Form 10-K and subsequent periodic and current reports we may file with the SEC.

Should one or more of these risks or uncertainties materialize, or should any of these assumptions prove to be incorrect, our actual operating and financial performance may vary in material respects from the performance projected in these forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as required by law, we undertake no obligation to update any forward-looking statement contained in this press release to reflect events or circumstances after the date on which it is made or to reflect the occurrence of anticipated or unanticipated events or circumstances, and we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. New factors that could cause our business not to develop as we expect emerge from time to time, and it is not possible for us to predict all of them. Further, we cannot assess the impact of each currently known or new factor on our results of operations or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements.

About Direct Digital Holdings
Direct Digital Holdings (Nasdaq: DRCT), owner of operating companies Colossus SSP, Huddled Masses, and Orange 142, brings state-of-the-art sell- and buy-side advertising platforms together under one umbrella company. Direct Digital Holdings’ sell-side platform, Colossus SSP, offers advertisers of all sizes extensive reach within general market and multicultural media properties. The Company’s subsidiaries Huddled Masses and Orange142 deliver significant ROI for middle market advertisers by providing data-optimized programmatic solutions at scale for businesses in sectors that range from energy to healthcare to travel to financial services. Direct Digital Holdings’ sell- and buy-side solutions generate billions of impressions per month across display, CTV, in-app and other media channels.

Contacts:
Investors:
Brett Milotte, ICR
Brett.Milotte@icrinc.com

Direct Digital Holdings Logo (PRNewsfoto/Direct Digital Holdings)

View original content to download multimedia:https://www.prnewswire.com/news-releases/direct-digital-holdings-announces-strategic-20-million-equity-reserve-facility-to-accelerate-growth-plan-302281770.html

SOURCE Direct Digital Holdings

Atlantic Union to Acquire Sandy Spring Bancorp in $1.6 Billion All-Stock Deal

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Atlantic Union Bank to acquire Sandy Spring Bancorp in a $1.6 billion all-stock deal.
– The combined company will have assets of $39.2 billion and expand its reach in Virginia and Maryland.
– Merger expected to close by the third quarter of 2025.

Atlantic Union Bankshares Corporation (NYSE: AUB) has announced its agreement to acquire Sandy Spring Bancorp (Nasdaq: SASR) in an all-stock transaction valued at approximately $1.6 billion. The deal will create the largest regional bank headquartered in the lower Mid-Atlantic, enhancing the combined company’s presence in key markets like Northern Virginia and Maryland.

Founded in 1868 and headquartered in Olney, Maryland, Sandy Spring Bank has $14.4 billion in assets, $11.7 billion in total deposits, and $11.5 billion in loans as of September 30, 2024. The newly combined company will have total assets of $39.2 billion, deposits of $32 billion, and loans of $29.8 billion. The merger will also allow Atlantic Union to nearly double its wealth management business by increasing assets under management by over $6.5 billion.

John C. Asbury, President and CEO of Atlantic Union, described the merger as a strategic move that fulfills a long-term vision to expand their banking presence from Baltimore through Washington D.C., Richmond, and Hampton Roads. “With today’s announcement, Atlantic Union will create a preeminent regional bank with Virginia as its linchpin,” said Asbury.

Sandy Spring Bank’s CEO, Daniel J. Schrider, echoed the enthusiasm, stating that the merger is the right long-term decision for shareholders, employees, and clients. Schrider emphasized the shared values between both organizations, particularly their commitment to community and people-first business practices.

Under the terms of the merger agreement, Sandy Spring shareholders will receive 0.900 shares of Atlantic Union common stock for each share of Sandy Spring common stock. The deal is valued at approximately $34.93 per share, reflecting an 18% premium to Sandy Spring’s closing stock price on October 18, 2024.

As part of the agreement, three members of Sandy Spring’s board of directors, including Schrider, will join the board of Atlantic Union. The merger is expected to close by the third quarter of 2025, pending regulatory approvals and shareholder consent.

Atlantic Union will also gain 53 additional branch locations through the merger, significantly strengthening its footprint in the Mid-Atlantic. Ron Tillett, Chairman of Atlantic Union’s Board of Directors, stated, “This combination creates a uniquely valuable franchise, enabling us to better serve our customers and communities while generating long-term shareholder value.”

The transaction has been unanimously approved by both boards of directors, and both companies plan to work closely to ensure a smooth integration process. A joint investor call is scheduled to discuss the merger and third-quarter earnings, reflecting both banks’ commitment to transparency and long-term growth.

Atlantic Union is headquartered in Richmond, Virginia, and operates 129 branches across Virginia, Maryland, and North Carolina. Sandy Spring, with over 50 locations, serves the Greater Washington D.C. area, offering a range of commercial and retail banking services.

Release – ACCO Brands Corporation Announces Third Quarter 2024 Earnings Webcast

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on ACCO

LAKE ZURICH, Ill.–(BUSINESS WIRE)– ACCO Brands Corporation (NYSE: ACCO) today announced that it will release its third quarter 2024 earnings after the market close on October 31, 2024. The Company will host a conference call and webcast to discuss the results on November 1 at 8:30 a.m. EDT. The webcast can be accessed through the Investor Relations section of www.accobrands.com and will be available for replay.

About ACCO Brands Corporation

ACCO Brands, the Home of Great Brands Built by Great People, designs, manufactures and markets consumer and end-user products that help people work, learn and play. Our widely recognized brands include AT-A-GLANCE®, Five Star®, Kensington®, Leitz®, Mead®, PowerA®, Swingline®, Tilibra® and many others. More information about ACCO Brands Corporation (NYSE: ACCO) can be found at www.accobrands.com.

Christopher McGinnis
Investor Relations
(847) 796-4320

Kori Reed
Media Relations
(224) 501-0406Source: ACCO Brands Corporation

Perfect Corp. (PERF) – An AI Company Positioned to Accelerate Revenue Growth

Posted on by cpereira@noblefcm.com


Monday, October 21, 2024

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Initiating coverage with Outperform rating. We are initiating coverage on Perfect Corp., an AI technology company, with an Outperform rating and $5 price target. The prospect of additional interest rate cuts should lead to an improving environment for the company to grow its enterprise client base, leading to enhanced revenue growth and improving margins. 

Seizing B2B and B2C opportunities. The company’s AI and AR technology powers its market leading virtual try-on service, used by beauty brands and retailers alike for skincare products and makeup. The company also leverages its technology to offer a suite of products direct to consumers through its apps. These include capabilities like AI-enhanced photo editing and generative AI.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

CVS Health Replaces CEO Karen Lynch Amid Earnings Struggles and Investor Pressure

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– CVS ousts CEO Karen Lynch, appointing David Joyner as the new Chief Executive.
– Lynch’s departure follows repeated earnings misses and rising investor concerns.
– CVS stock dropped 7.9% following the leadership change announcement.

CVS Health has made a major leadership change, replacing CEO Karen Lynch with David Joyner, following a period of financial struggles and pressure from activist investors. Joyner, a seasoned executive with extensive experience in pharmacy benefits management (PBM), took over as CEO on Thursday. His appointment comes as CVS grapples with missed earnings targets, rising medical costs, and competition from rivals like Amazon and Walmart.

Shares of CVS fell nearly 8% after the announcement, adding to a 19% drop this year. The company also revealed that its third-quarter earnings would miss Wall Street expectations, prompting CVS to pull its 2024 earnings guidance due to high medical expenses. In a memo to employees, Joyner acknowledged the challenges ahead and called for support in stabilizing the company’s operations. He emphasized the need for operational and financial improvements to maintain CVS’s position as a leading healthcare provider.

CVS’s financial troubles stem largely from its health benefits division, particularly its Aetna insurance arm, where medical costs have outpaced expectations. The company announced a $1.1 billion charge to cover excess medical costs, further straining its finances. Analysts had anticipated issues in the health benefits segment, but CVS’s medical loss ratio of 95.2% for the third quarter was worse than expected, raising concerns among investors.

In response to these difficulties, hedge fund Glenview Capital Management, a CVS investor, has been pushing for changes within the company. Glenview supported the decision to replace Lynch, viewing it as a necessary step toward improving CVS’s financial performance and governance. In a statement, Glenview expressed interest in working with Joyner to enhance the company’s operations and create value for stakeholders.

Lynch’s departure ends a tumultuous tenure as CEO, which began in February 2021. She led CVS’s expansion into healthcare services, acquiring companies like Oak Street Health and Signify Health to strengthen CVS’s Medicare Advantage business. However, the timing of these acquisitions coincided with tighter restrictions on Medicare spending imposed by the Biden administration, which negatively impacted CVS’s margins.

CVS also faced setbacks in its PBM division, Caremark, losing a significant contract with Centene Corp., which chose to partner with Cigna instead. Caremark is also under investigation by the Federal Trade Commission (FTC) for its role in rising drug prices, including insulin. Joyner, who previously led Caremark, defended the company’s practices before Congress earlier this year, and his expertise in this area is expected to help CVS navigate regulatory challenges and increased competition.

The health benefits segment remains CVS’s most significant concern, particularly as the company experienced rapid growth in Medicare Advantage membership in 2024. However, the costs associated with that growth have exceeded projections, prompting CVS to withdraw its earnings forecast for 2024. The company had previously lowered its earnings guidance several times this year, with the most recent estimate between $6.40 and $6.55 per share. Analysts had already predicted a 25% drop in earnings per share for 2024 compared to the previous year, and that figure is expected to fall further.

With Joyner at the helm, CVS faces a critical moment. The board unanimously supported his appointment, and he is tasked with steering the company through its current challenges and restoring investor confidence in its future.

The AI Energy Revolution: Is Nuclear Power the Next Frontier?

Posted on by slightbourne@noblecapitalmarkets.com
Key Points:
– Big Tech is driving nuclear energy investments to meet AI data center demands.
– SMRs (Small Modular Reactors) are gaining attention, but are still in the experimental stage.
– Few public investment options exist in nuclear power, though related stocks have surged.

Nuclear power is emerging as a key player in the race to meet the enormous energy demands of AI-generating data centers, as Big Tech giants look for reliable, clean energy sources to fuel their operations. In recent weeks, Microsoft, Google, and Amazon have each announced significant investments in nuclear energy, signaling that this technology could be poised for a major comeback in the U.S. energy landscape.

Microsoft’s partnership with Constellation Energy to restart the shuttered Three Mile Island nuclear reactor, Google’s collaboration with Kairos Power to harness Small Modular Reactors (SMRs), and Amazon’s $500 million investment in SMR developer X-Energy highlight a growing trend. These tech giants are betting on nuclear power as a sustainable solution to the skyrocketing energy needs of AI, cloud computing, and data center operations.

For decades, nuclear energy has contributed about 20% of the U.S. electricity supply. However, the industry has stagnated, facing stringent regulatory requirements and high costs that have made it difficult for new reactors to come online. The recent openings of reactors at the Vogtle plant in Georgia were the first new units in seven years, underlining the slow pace of expansion in this sector.

But as Big Tech’s energy consumption continues to grow, driven by the demands of AI and other data-heavy applications, nuclear power has come back into focus. The goal of SMRs is to create smaller, more flexible reactors that are cost-effective and can be built closer to the grid. These reactors have the potential to power everything from industrial operations to sprawling data centers. However, it’s important to note that these reactors are still in the experimental stage in the U.S. The first fully operational units are not expected to be online until the early 2030s, with Microsoft’s project at Three Mile Island targeting a restart by 2028.

Investors looking to capitalize on the nuclear resurgence have few direct options. Companies like NuScale Power (SMR) and Oklo (OKLO) have seen their stock prices soar as investor interest in nuclear technologies grows, but they remain speculative, given the unproven nature of SMRs. NuScale, for example, has seen its shares rise by over 450% this year alone, while Oklo, backed by OpenAI’s Sam Altman, has gained more than 80% since going public through a SPAC.

This shift toward nuclear also ties into broader trends we’ve covered recently, including the increasing focus on renewable energy solutions to power data centers. For instance, Amazon’s recent investments in small modular reactors through X-Energy are a continuation of its efforts to secure clean energy sources, mirroring its $500 million commitment to clean energy projects we wrote about earlier this week. These investments by tech companies not only signal a growing need for energy but also show a strategic shift toward sustainable, scalable solutions.

Energy companies, particularly those involved in nuclear power, utilities, and uranium production, have been significant beneficiaries of this renewed interest. Stocks of utility companies and uranium producers like Cameco (CCJ) and Uranium Energy (UEC) are near record highs as investors seek exposure to this trend. In fact, as we mentioned in our analysis of Wolfspeed’s $750 million chips grant, the intersection of tech and energy—especially AI—continues to drive investment across multiple sectors.

As AI technology continues to evolve, one thing is clear: the next frontier for tech could be nuclear power. With billions of dollars flowing into this once-stagnant industry, nuclear energy may soon be a critical component of the AI revolution. While there are still significant hurdles to overcome, Big Tech’s commitment to nuclear energy signals a major shift in how the world’s largest companies are planning to power the future.

Release – Comtech Announces Transformation Strategy and Capital Structure Update

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on CMTL

Board of Directors Discloses Strategic Alternatives Process for Terrestrial & Wireless Networks Segment; Comtech to Become a Pure-Play Satellite and Space Communications Company

Company Amends Credit Facility and Enters into New Subordinated Unsecured Term Loan Facility

CHANDLER, Ariz. – Comtech (NASDAQ: CMTL) (the “Company”), a global technology leader, today announced that its Board of Directors and management team are executing a strategy to transform Comtech into a pure-play satellite and space communications company and provided a capital structure update.

Ongoing and future actions supporting Comtech’s transformation strategy include:

  • An exploration of strategic alternatives for the Company’s Terrestrial & Wireless Networks (“T&W”) segment, which is well underway;
  • The pursuit of further portfolio-shaping opportunities to enhance profitability, efficiency and focus; and
  • The implementation of additional operational initiatives to align Comtech’s go-forward cost structure with a pure-play focus on satellite and space communications.

Comtech’s Board of Directors noted, “Comtech is in the midst of a transformational journey. Earlier this year, we enhanced our T&W segment with a new management team to drive growth and improved profitability. Given the strength and value we see in our T&W segment, we initiated a process to explore strategic alternatives for this business to unlock value for Comtech shareholders. We believe the best path forward for shareholders is the creation of a pure-play satellite and space communications company with a simplified capital structure, streamlined operations and strong balance sheet. This strategy is the product of months of careful evaluation conducted with the assistance of management and independent advisors. We look forward to providing an update on the strategic alternatives process and broader strategy at key milestones.”

Strategic Alternatives Process for the T&W Segment

Comtech’s T&W business is a leading provider of next-generation 911 (“NG911”) infrastructure and solutions for state and local governments and telecom carriers across North America. Enhanced by the leadership of new executive management, in fiscal 2024, the T&W segment has more than doubled its bookings of orders for next-generation solutions. Additionally, as a result of a more refined strategic focus and the achievement of certain cost-containment and operational efficiency measures, T&W is on track to delivering strong year-over-year bottom line performance.

Comtech’s recent T&W wins and milestones include a long-term competitive contract renewal for NG911 solutions in the Commonwealth of Massachusetts; the buildout of Pennsylvania’s NG911 statewide network; a mandate for the Toronto Police Service’s NG911 solution; a long-term NG911 renewal with the North Central Texas Emergency Communications District; a statewide NG911 solution in the Northeast U.S. in partnership with Consolidated Communications; and multi-province NG911 deployments in Canada. Demand for these solutions is expected to continue growing following a July 2024 ruling by the U.S. Federal Communications Commission to advance the nationwide transition to NG911.

The Board had previously retained independent financial advisors to assist in its strategic review earlier this year and, in recent months, commenced a strategic alternatives process for the T&W business.

The Board added, “Comtech deeply values its T&W customers, who put their trust in our best-in-class public safety solutions to keep their communities and people connected in their most critical moments. We expect to move forward with a partner who will focus on this attractive business and its customers, talented team members and valued service providers.”

There can be no assurance that the exploration of strategic alternatives will result in a transaction or other strategic changes or outcomes. There is no timeframe for the conclusion of the process, and the Company does not intend to comment further regarding this matter unless and until further disclosure is determined to be appropriate or necessary.

Pure-Play Satellite and Space Communications Company

Comtech’s Satellite & Space Communications (“S&S”) segment is a U.S.-based, leading provider of advanced modems and high-power amplifier technologies, and a market leader in troposcatter technologies. The S&S segment has an innovative portfolio of these mission-critical technologies and serves some of the world’s largest defense contractors and allied foreign governments, as well as multiple U.S. government agencies, including branches of the U.S. Armed Forces, U.S. Department of Defense (“DoD”) and U.S. Space Force (“USSF”), among others.

The S&S business operates in large and growing end markets that benefit from multiple tailwinds and demand-drivers, including growing global geopolitical tensions, rising global defense spending, and high barriers to entry. Further, these end markets are undergoing technology upgrade cycles and modernization initiatives that are expected to underpin demand for years to come. Fueling these cycles are the USSF’s Commercial Space Strategy and the DoD’s Joint All Domain Command and Control approach, which are expected to generate strong demand for the S&S business’ next-generation digital solutions. Today, only a limited number of companies, including Comtech, can serve the complex needs of the U.S. and other governments and meet this demand.

Proceeds from the potential divestiture of T&W would enable Comtech to substantially simplify its capital structure and strengthen its balance sheet. Paired with additional targeted portfolio optimization and a singular focus on satellite and space communications, the go-forward company would be well-positioned to capitalize on growth opportunities.

Portfolio-Shaping and Operational Initiatives

In connection with the Board’s transformative strategy, the Company has undertaken a detailed evaluation of its S&S portfolio to identify opportunities to divest, separate and/or rationalize businesses or facilities that are not core to Comtech’s go-forward focus.

Consistent with this effort, in its fourth fiscal quarter, Comtech made the decision to exit its subsidiary operations in Basingstoke, United Kingdom. The U.K. operations were established in connection with the prior management team’s 2020 acquisition of CGC Technology Limited, which primarily served customers in Europe. Following the acquisition, Comtech continued to invest in the Basingstoke facility to advance LEO constellation-based antenna technologies in anticipation of a significant production order. Taking into consideration the significant ongoing investment as well as unfavorable contract terms on prospective antenna sales, the Board concluded the U.K. business would not generate an attractive return on invested capital and made the decision to exit these operations. After anticipated restructuring charges associated with the exit of the Basingstoke operations, Comtech expects to realize approximately $10 million of annual cash savings.

In addition to its ongoing efforts to improve the cash conversion cycle and manage the balance sheet, Comtech has been working with independent advisors to identify opportunities to align the Company’s cost structure with its go-forward focus on satellite and space communications.

Furthermore, over the past several months, Comtech has conducted an intensive review of its product portfolio to focus future investment on the Company’s most strategic, high-margin revenue opportunities within its S&S portfolio. While anticipated to improve the Company’s profitability in future periods, such actions may result in near-term restructuring charges.

Amended Credit Agreement and New Subordinated Term Loan Facility

On October 16, 2024, Comtech filed a Form 12b-25 with the Securities and Exchange Commission (“SEC”) noting that it is unable to file its Annual Report on Form 10-K for the period ended July 31, 2024 within the prescribed time period without unreasonable effort or expense, and that the Company anticipates reporting significantly lower-than-expected performance, primarily in its S&S segment, in the fourth fiscal quarter.

In light of this, the Company entered into an amendment to its existing credit facility dated June 17, 2024. Among other things, the amendment waives defaults or events of default in connection with the Company’s Net Leverage Ratio and Fixed Charge Coverage Ratio covenants for the fourth fiscal quarter. To cure defaults, maintain appropriate liquidity and support the Company’s transformation initiatives, Comtech entered into a new $25.0 million subordinated unsecured term loan facility with the existing holders of the Company’s convertible preferred stock. Within the terms of the amended credit facility, this new subordinated unsecured term loan allows the Company to maintain a consistent level of borrowing capacity.

Additional information related to the Company’s credit facilities can be found in a Form 8-K that will be filed with the SEC.

Advisors

Imperial Capital, LLC is acting as financial advisor for the T&W strategic alternatives process. Sidley Austin LLP and Paul, Weiss, Rifkind, Wharton & Garrison LLP are serving as legal counsel.

About Comtech

Comtech Telecommunications Corp. is a leading global technology company providing terrestrial and wireless network solutions, NG911 emergency services, satellite and space communications technologies, and cloud native capabilities to commercial and government customers around the world. Our unique culture of innovation and employee empowerment unleashes a relentless passion for customer success. With multiple facilities located in technology corridors throughout the United States and around the world, Comtech leverages its global presence, technology leadership, and decades of experience to create the world’s most innovative communications solutions. For more information, please visit www.comtech.com.

Cautionary Note Regarding Forward-Looking Statements

Certain information in this press release contains, and oral statements made by our representatives from time to time may contain, forward-looking statements. Forward-looking statements can be identified by words such as: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “future,” “goal,” “outlook,” “intend,” “likely,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “strategy,” “target,” “will,” “would,” and similar references to future periods. Forward-looking statements include, among others, statements regarding our expectations for the strategic alternatives process regarding our T&W segment, our expectations for further portfolio-shaping opportunities, our expectations for the other operational initiatives described in this press release, our expected financial results for the year and quarter ended July 31, 2024, the intended use of proceeds from the financing transactions described in this press release, our expectations for completing further financing initiatives, our future performance and financial condition, our plans to address our ability to continue as a going concern, the plans and objectives of our management and our assumptions regarding such future performance, financial condition, and plans and objectives that involve certain significant known and unknown risks and uncertainties and other factors not under our control which may cause our actual results, future performance and financial condition, and achievement of our plans and objectives of our management to be materially different from the results, performance or other expectations implied by these forward-looking statements. Factors that could cause actual results to differ materially from current expectations include, among other things: the outcome and effectiveness of the initiatives described in this press release, our ability to access capital and liquidity so that we are able to continue as a going concern; our ability to implement changes in our executive leadership; the possibility that the expected synergies and benefits from our strategic activities will not be fully realized, or will not be realized within the anticipated time periods; the risk that acquired businesses will not be integrated successfully; impacts from and uncertainties regarding future actions that may be taken by Michael Porcelain and stockholders affiliated with him in furtherance of their nominations of director candidates for election at the Company’s Fiscal 2024 Annual Meeting of Stockholders; the possibility of disruption from acquisitions or dispositions, making it more difficult to maintain business and operational relationships or retain key personnel; the risk that we will be unsuccessful in implementing a tactical shift in our Satellite and Space Communications segment away from bidding on large commodity service contracts and toward pursuing contracts for our niche products and solutions with higher margins; the nature and timing of our receipt of, and our performance on, new or existing orders that can cause significant fluctuations in net sales and operating results; the timing and funding of government contracts; adjustments to gross profits on long-term contracts; risks associated with international sales; rapid technological change; evolving industry standards; new product announcements and enhancements; changing customer demands and/or procurement strategies and our ability to scale opportunities and deliver solutions to current and prospective customers; changes in prevailing economic and political conditions, including as a result of Russia’s military incursion into Ukraine, the Israel-Hamas war and attacks in the Red Sea region; changes in the price of oil in global markets; changes in prevailing interest rates and foreign currency exchange rates; risks associated with our legal proceedings, customer claims for indemnification, and other similar matters; risks associated with our obligations under our credit facilities; risks associated with our large contracts; risks associated with supply chain disruptions; and other factors described in this and our other filings with the Securities and Exchange Commission (“SEC”). However, the risks described above are not the only risks that we face. Additional risks and uncertainties, not currently known to us or that do not currently appear to be material, may also materially adversely affect our business, financial condition and/or operating results in the future. We describe risks and uncertainties that could cause actual results and events to differ materially in the “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and “Quantitative and Qualitative Disclosures about Market Risk” sections of our SEC filings. We do not intend to update or revise publicly any forward-looking statements, whether because of new information, future events, or otherwise, except as required by law.

Further, the Company’s financial closing procedures for the fiscal year and quarter ended July 31, 2024 are not yet complete. The expected financial results for the fiscal year and quarter ended July 31, 2024 described herein are estimates based on information available to management as of the date of this press release, have not been audited by the Company’s independent registered accounting firm, and are subject to change. It is possible that the final results may vary from these preliminary estimates upon completion of closing procedures and finalization of the Company’s audited consolidated financial statements.

Investor Relations

Maria Ceriello

631-962-7102

investors@comtech.com

Media

Jamie Clegg

480-532-2523

jamie.clegg@comtech.com

Jed Repko / Aura Reinhard

Joele Frank, Wilkinson Brimmer Katcher

212-355-4449

Release – NN, Inc. to Hold Third Quarter 2024 Earnings Conference Call on Friday, November 1, 2024

Posted on by dburczyk@noblecapitalmarkets.com

Research News and Market Data on NNBR

CHARLOTTE, N.C., Oct. 17, 2024 (GLOBE NEWSWIRE) — NN, Inc. (NASDAQ: NNBR), a global diversified industrial company that engineers and manufactures high-precision components and assemblies, announced today that it will release its third quarter 2024 financial results for the period ended September 30th, 2024, after the close of the market on Thursday, October 31st, 2024. The Company will hold a related conference call on Friday, November 1st, 2024, at 9:00 a.m. E.T. Participants on the call are asked to register five to ten minutes prior to the scheduled start time by dialing 1-877-255-4315 and from outside the U.S. at 1-412-317-6579.

The conference call will be webcast simultaneously and in its entirety through the NN, Inc. Investor Relations website. Shareholders, media representatives and others may participate in the webcast by registering through the Investor Relations section on the company’s website at https://investors.nninc.com/.

For those who are unavailable to listen to the live call, a replay will be available shortly after the call on NN’s website through November 1st, 2025.

About NN, Inc.
NN, Inc., a global diversified industrial company, combines advanced engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision components and assemblies for a variety of markets on a global basis. Headquartered in Charlotte, North Carolina, NN has facilities in North America, Europe, South America, and Asia. For more information about the company and its products, please visit www.nninc.com.

Investor & Media Contacts:
Joe Caminiti or Stephen Poe, Investors
Tim Peters or Emma Brandeis, Media
NNBR@alpha-ir.com 312-445-2870

Source: NN, Inc.